News zum Sektor Gesundheit aus Island

 

Announcement no. 38/2026 Interim Report Q2 2026 Sveinn Sölvason, President and CEO, comments: “Sales in Q2 2026 were USD 259 million, representing 11% reported growth and 6% organic growth. Strong double-digit Prosthetics & Neuro Orthotics growth in Q2, supported by excellent execution, robust volume growth in EMEA and APAC, and successful new product launches. Bracing & Supports delivered moderate growth in the quarter, while Patient Care declined. In Patient Care, we continue to see encouraging progress, with most of our clinics delivering increased productivity and...

Announcement no. 37/2026 17 July 2026 Reykjavik, Iceland/Copenhagen, Denmark, 17 July 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced that the Company has decided to initiate a new share buyback program (the “Program”) on Monday, 20 July 2026. The Program will be carried out in accordance with Regulation No. 596/2014 of the European Parliament and of the Council on market abuse ("MAR"), and the Commission's delegated regulation 2016/1052. The purpose of the Program is to reduce the Company's share capital...

Announcement no. 36/2026 17 July 2026 Reykjavik, Iceland/Copenhagen, Denmark, 17 July 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced the completion of the share buyback program, which was announced in Company Announcement no. 3/2025 dated 7 February 2025. Following are the last transactions carried out under the current share buyback program. Transaction No. of Avg. purchase price in DKK Transaction value in DKK date shares 13 July 10,000 26.47...

Announcement no. 35/2026 13 July 2026 Reykjavik, Iceland/Copenhagen, Denmark, 13 July 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 61/2025 dated 23 December 2025. During the period 6 July  to 10 July 2026 Embla Medical has acquired 50,106 shares under the Program at the average price of DKK 26.81. Following the transactions below, the Company holds 2,195,201 shares, corresponding to 0.52% of the Company's...

Reykjavik, Iceland/Copenhagen, Denmark, 7 July 2026. Embla Medical (Nasdaq Copenhagen: EMBLA) will publish its Q2 2026 Report on July 21, 2026, at 7:00 CET. A conference call will be hosted on the same day at 9:00 CET / 7:00 GMT / 3:00am EST. The event will be hosted by Sveinn Solvason, President and CEO, and G. Arna Sveinsdottir, CFO. The call will include a review of the quarterly results and will be held in English. Slides used in the presentation will be made available on the company website at the following link: https://www.emblamedical.com/investors To participate in the...

Announcement no. 34/2026 6 July 2026 Reykjavik, Iceland/Copenhagen, Denmark, 6 July 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 61/2025 dated 23 December 2025. During the period 29 June to 3 July 2026 Embla Medical has acquired 57,000 shares under the Program at the average price of DKK 26.95. Following the transactions below, the Company holds 2,145,095 shares, corresponding to 0.50% of the Company's...

Announcement no. 33/2026 29 June 2026 Reykjavik, Iceland/Copenhagen, Denmark, 29 June 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 61/2025 dated 23 December 2025. During the period 22 June to 26 June 2026 Embla Medical has acquired 113,000 shares under the Program at the average price of DKK 25.96. Following the transactions below, the Company holds 2,088,095 shares, corresponding to 0.49% of the Company'...

Announcement no. 32/2026 22 June 2026 Reykjavik, Iceland/Copenhagen, Denmark, 22 June 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 61/2025 dated 23 December 2025. During the period 15 June to 19 June 2026 Embla Medical has acquired 125,000 shares under the Program at the average price of DKK 26.89. Following the transactions below, the Company holds 1,975,095 shares, corresponding to 0.46% of the Company'...

Announcement no. 31/2026 15 June 2026 Reykjavik, Iceland/Copenhagen, Denmark, 15 June 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 61/2025 dated 23 December 2025. During the period 8 June to 12 June 2026 Embla Medical has acquired 107,000 shares under the Program at the average price of DKK 26.91. Following the transactions below, the Company holds 1,850,095 shares, corresponding to 0.43% of the Company's...

Announcement no. 30/2026 8 June 2026 Reykjavik, Iceland/Copenhagen, Denmark, 8 June 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 61/2025 dated 23 December 2025. During the period 1 June to 4 June 2026 Embla Medical has acquired 58,784 shares under the Program at the average price of DKK 26.98. Following the transactions below, the Company holds 1,743,095 shares, corresponding to 0.41% of the Company's...

Announcement no. 29/2026 1 June 2026 Reykjavik, Iceland/Copenhagen, Denmark, 1 June 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 61/2025 dated 23 December 2025. During the period 26 May to 29 May 2026 Embla Medical has acquired 83,854 shares under the Program at the average price of DKK 27.04. Following the transactions below, the Company holds 1,684,311 shares, corresponding to 0.40% of the Company's...

Announcement no. 28/2026 26 May 2026 Reykjavik, Iceland/Copenhagen, Denmark, 26 May 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 61/2025 dated 23 December 2025. During the period 18 May to 22 May 2026 Embla Medical has acquired 108,000 shares under the Program at the average price of DKK 26.32. Following the transactions below, the Company holds 1,600,457 shares, corresponding to 0.38% of the Company's...

Announcement no. 27/2026 18 May 2026 Reykjavik, Iceland/Copenhagen, Denmark, 18 May 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 61/2025 dated 23 December 2025. During the period 11 May to 13 May 2026 Embla Medical has acquired 101,000 shares under the Program at the average price of DKK 26.75. Following the transactions below, the Company holds 1,492,457 shares, corresponding to 0.35% of the Company's...

Announcement no. 26/2026 11 May 2026 Reykjavik, Iceland/Copenhagen, Denmark, 11 May 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 61/2025 dated 23 December 2025. During the period 4 May to 8 May 2026 Embla Medical has acquired 94,015 shares under the Program at the average price of DKK 27,21. Following the transactions below, the Company holds 1,391,457 shares, corresponding to 0.33% of the Company's total...

Announcement no. 25/2026 4 May 2026 Reykjavik, Iceland/Copenhagen, Denmark, 4 May 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 61/2025 dated 23 December 2025. During the period 27 April to 1 May 2026 Embla Medical has acquired 170,000 shares under the Program at the average price of DKK 26.95. Following the transactions below, the Company holds 1,297,442 shares, corresponding to 0.30% of the Company's...

Announcement no. 24/2026 Interim Report Q1 2026 Sveinn Sölvason, President and CEO, comments: “Sales in the first quarter of 2026 reached USD 232 million, representing reported growth of 15% and organic growth of 4%. We delivered strong performance in Prosthetics & Neuro Orthotics, driven by continued momentum and solid volume growth across regions and categories. Bracing & Supports delivered moderate growth, while Patient Care experienced a softer quarter, largely driven by timing effects in Europe. We are seeing more favorable trends in the U.S. Patient Care business and...

Announcement no. 23/2026 27 April 2026 Reykjavik, Iceland/Copenhagen, Denmark, 27 April 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 61/2025 dated 23 December 2025. During the period 20 April to 24 April 2026 Embla Medical has acquired 148,000 shares under the Program at the average price of DKK 28.14. Following the transactions below, the Company holds 1,127,442 shares, corresponding to 0.26% of the...

Announcement no. 22/2026 20 April 2026 Reykjavik, Iceland/Copenhagen, Denmark, 20 April 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 61/2025 dated 23 December 2025. During the period 13 April to 17 April 2026 Embla Medical has acquired 121,000 shares under the Program at the average price of DKK 28.12. Following the transactions below, the Company holds 979,442 shares, corresponding to 0.23% of the...

Reykjavik, Iceland/Copenhagen, Denmark, 20 April 2026. Embla Medical (Nasdaq Copenhagen: EMBLA) will publish its Q1 2026 Report on April 28, 2026, at 7:00 CET. A conference call will be hosted on the same day at 9:00 CET / 7:00 GMT / 3:00am EST. The event will be hosted by Sveinn Solvason, President and CEO, and G. Arna Sveinsdottir, CFO. The call will include a review of the quarterly results and will be held in English. Slides used in the presentation will be made available on the company website at the following link: https://www.emblamedical.com/investors To participate in the...

Announcement no. 21/2026 13 April 2026 Reykjavik, Iceland/Copenhagen, Denmark, 13 April 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 61/2025 dated 23 December 2025. During the period 7 April  to 10 April 2026 Embla Medical has acquired 60,000 shares under the Program at the average price of DKK 27.18. Following the transactions below, the Company holds 858,442 shares, corresponding to 0.20% of the Company'...